Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
Abstract Background Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO® Risk Evaluation and Mitigation Strategy; REMS) due to ris...
Main Authors: | Svetlana Garafola, Elizabeth Shiferaw, Vikram Dev |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-06-01
|
Series: | Drugs - Real World Outcomes |
Online Access: | https://doi.org/10.1007/s40801-023-00372-4 |
Similar Items
-
Efficacy of brexanolone in postpartum depression
by: C. M. Rodríguez Mercado
Published: (2023-03-01) -
Treating Postpartum Depression: What Do We Know about Brexanolone?
by: Muneeza Ali, et al.
Published: (2021-07-01) -
Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis
by: Aaron Salwan, PharmD, MPH, BCPP, et al.
Published: (2023-01-01) -
Brexanolone: an allosteric modulator of GABA-A receptors in the rapid treatment of postpartum depression
by: Samet Kose, et al.
Published: (2017-10-01) -
Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
by: Tigran Makunts, et al.
Published: (2023-08-01)